论文部分内容阅读
作者采用重组人白细胞介素-3(rhIL-3)对造血功能正常和骨髓衰竭的两组恶性肿瘤患者进行了治疗,以分析这种多向造血刺激因子的毒性和生物学效应。 28例恶性肿瘤患者,男22、女6例,年龄18～77(中数54)岁。19例患者造血功能正常,其中17例曾接受过化疗或放疗;9例患者骨髓功能衰竭和全血细胞减少,主要因长期化疗和肿瘤细胞浸润(3例)所致,化疗结束已3周～14个月(中数2.5个月),无自发性造血恢复的证据,3例患者曾接受粒-
The authors treated two groups of malignant tumor patients with normal hematopoietic function and bone marrow failure using recombinant human interleukin-3 (rhIL-3) to analyze the toxicity and biological effects of this multi-directional hematopoietic stimulator. 28 cases of malignant tumor patients, male 22, female 6 cases, aged 18 to 77 (median 54) years old. Nineteen patients had normal hematopoietic function, of whom 17 had received chemotherapy or radiotherapy. Nine patients had bone marrow failure and pancytopenia, mainly due to long-term chemotherapy and tumor cell infiltration (3 cases). The chemotherapy was completed from 3 weeks to 14 Months (median 2.5 months), no evidence of spontaneous hematopoietic recovery, 3 patients had received granulocyte -